Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:1703 |
Name | Richter's syndrome |
Definition | |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer hematologic cancer leukemia lymphoid leukemia chronic lymphocytic leukemia Richter's syndrome |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03218683 | Phase I | AZD5991 | Study of AZD5991 in Relapsed or Refractory Haematologic Malignancies. | Terminated | USA | 0 |
NCT03263637 | Phase I | AZD4573 | Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies | Completed | NLD | GBR | DEU | 0 |
NCT03765177 | Phase Ib/II | CLIC-1901 | CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies (CLIC-01) | Recruiting | CAN | 0 |
NCT03884998 | Phase I | Copanlisib + Nivolumab | Copanlisib and Nivolumab in Treating Participants With Richter's Transformation or Transformed Indolent Non-Hodgkin's Lymphoma | Active, not recruiting | USA | 0 |
NCT03892044 | Phase I | Duvelisib + Nivolumab | Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma | Completed | USA | 0 |
NCT04623541 | Phase Ib/II | Epcoritamab-bysp Epcoritamab-bysp + Venetoclax Cyclophosphamide + Doxorubicin + Epcoritamab-bysp + Prednisone + Rituximab + Vincristine Sulfate Epcoritamab-bysp + Lenalidomide | Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome (EPCORE™ CLL-1) | Recruiting | USA | NLD | ITA | ISR | GBR | FRA | ESP | DNK | DEU | CZE | BEL | AUS | 0 |
NCT04978779 | Phase I | VIP152 | A Study to Evaluate VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome | Terminated | USA | POL | 0 |
NCT05588440 | Phase Ib/II | Cyclophosphamide + Fludarabine ONCT-808 | A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies | Terminated | USA | 0 |
NCT05665530 | Phase I | PRT2527 | A Study of PRT2527 in Participants With Relapsed/Refractory Hematologic Malignancies | Recruiting | USA | POL | ITA | GBR | FRA | DEU | CHE | CAN | AUS | 1 |
NCT05672173 | Phase II | Cyclophosphamide + Fludarabine + Ibrutinib + Lisocabtagene maraleucel | Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation | Recruiting | USA | 0 |
NCT05672251 | Phase II | Loncastuximab tesirine-lpyl + Mosunetuzumab-axgb | Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Recruiting | USA | 0 |
NCT05873712 | Phase II | Cyclophosphamide + Fludarabine + Lisocabtagene maraleucel + Zanubrutinib | Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome | Recruiting | USA | 0 |
NCT06043674 | Phase II | Tocilizumab Atezolizumab + Glofitamab-gxbm + Obinutuzumab Glofitamab-gxbm + Obinutuzumab + Polatuzumab vedotin-piiq Glofitamab-gxbm + Obinutuzumab | A Phase 2 Study of Glofitamab as Monotherapy or in Combination With Polatuzumab Vedotin or Atezolizumab in Richter's Transformation | Recruiting | USA | 0 |
NCT06191887 | Phase I | Bendamustine BAFFR-CAR T cells Cyclophosphamide + Fludarabine | B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies | Recruiting | USA | 0 |
NCT06227026 | Phase I | Anti-CD19 CAR-T cells | Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ Malignancies (PRODIGY) | Recruiting | USA | 0 |
NCT06247540 | Phase II | Nivolumab + Rituximab + Venetoclax | Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Withdrawn | USA | 0 |